MRI成像技术在非酒精性脂肪性肝病患者肝脏评估中的作用

摘要/Abstract

摘要： 随着全球肥胖和2型糖尿病发病率上升,非酒精性脂肪性肝病(NAFLD)已成为全世界最常见的肝脏疾病。目前在NAFLD肝脏脂肪变性及纤维化评估诊断中应用较多的MRI成像技术有质子密度脂肪分数(PDFF)测量、定量MRI T1 mapping及磁共振弹性成像(MRE)。本文就MRI成像技术在NAFLD患者肝脏评估中的作用进行综述。

李卫侠, 陈克敏. MRI成像技术在非酒精性脂肪性肝病患者肝脏评估中的作用[J]. 肝脏, 2024, 29(2): 154-156.

[1] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1): 11-20.
[2] Pennisi G, Enea M, Falco V, et al. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes[J]. Hepatology,2023,78(1): 195-211.
[3] Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts[J]. BMC Med,2019,17(1): 95.
[4] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update[J]. J Hepatol,2021,75(3): 659-689.
[5] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology,2023,77(5): 1797-1835.
[6] Loomba R, Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH[J]. Gastroenterology,2015,149(2): 278-281.
[7] Ekstedt M, Hagstr?m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J]. Hepatology,2015,61(5): 1547-1554.
[8] Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C[J]. Hepatology, 2003,38(6): 1449-1457.
[9] Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD[J]. Nat Rev Endocrinol,2022,18(1): 55-66.
[10] Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies[J]. Lancet Diabetes Endocrinol,2019,7(4): 313-324.
[11] Xia T, Du M, Li H, et al. Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk[J]. Radiology,2023,309(1): e231007.
[12] Micek M, Aebisher D, Surówka J, et al. Applications of T(1) and T(2) relaxation time calculation in tissue differentiation and cancer diagnostics-a systematic literature review[J]. Front Oncol,2022,12: 1010643.
[13] Terzi F, Camargo GC, Parente DB, et al. How Cardiac Fibrosis Assessed via T1 Mapping Is Associated with Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease[J]. J Clin Med,2023,12(23): 7381.
[14] Hoffman DH, Ayoola A, Nickel D, et al. T1 mapping, T2 mapping and MR elastography of the liver for detection and staging of liver fibrosis[J]. Abdom Radiol (NY),2020,45(3): 692-700.
[15] Duan T, Jiang H, Xia C, et al. Assessing Liver Function in Liver Tumors Patients: ,The Performance of T1 Mapping and Residual Liver Volume on Gd-EOBDTPA-Enhanced MRI[J]. Front Med (Lausanne),2020,7: 215.
[16] Li J, Gao X, Dominik Nickel M, et al. Native T1 mapping for differentiating the histopathologic type, grade, and stage of rectal adenocarcinoma: a pilot study[J]. Cancer Imaging,2022,22(1): 30.
[17] Muthupillai R, Lomas DJ, Rossman PJ, et al. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves[J]. Science,1995,269(5232): 1854-1857.
[18] Kennedy P, Wagner M, Castéra L, et al. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions[J]. Radiology,2018,286(3): 738-763.
[19] Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis[J]. Gut,2020,69(7): 1343-1352.
[20] Yoneda M, Nakajima A. The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities[J]. Hepatology,2023,78(4): 1020-1022.
[21] Li J, Lu X, Zhu Z, et al. Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH[J]. Hepatology,2023,78(4): 1200-1208.
[22] Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis[J]. Gut,2021,70(10): 1946-1953.
[23] Lee JS, Lee HW, Kim BK, et al. Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria[J]. Front Med (Lausanne),2022,9: 869190.
[24] Cardoso AC, Tovo CV, Leite NC, et al. Validation and Performance of FibroScan^○R-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease[J]. Dig Dis Sci,2022,67(11): 5272-5279.

MRI成像技术在非酒精性脂肪性肝病患者肝脏评估中的作用

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	董琳菲, 王艳. 细胞衰老在非酒精性脂肪性肝病中的作用与机制[J]. 肝脏, 2024, 29(2): 149-151.
[2]	邢翔宇, 牛俊奇. 代谢相关脂肪性肝病药物研发进展[J]. 肝脏, 2024, 29(1): 5-9.
[3]	吴雯玥, 孙亚朦, 尤红. 肝纤维化逆转:小进步尚待大突破[J]. 肝脏, 2024, 29(1): 13-15.
[4]	赵东志, 李国东, 常媛媛, 曹哲丽, 赵雅娟. 非酒精性脂肪性肝病患者C/RL-r、APRI、FIB-4水平与肝纤维化发生的相关性[J]. 肝脏, 2024, 29(1): 68-72.
[5]	吴彬彬, 徐小琴, 顾星星, 解其华. 脂肪肝诊断中ElastPQ弹性成像技术检测肝硬度与肝纤维化评分及FIB-4指数的相关性分析[J]. 肝脏, 2024, 29(1): 73-76.
[6]	张维, 刘清林, 张慢, 安阳, 曹睦涵. sTfR、肝脾CT比值与老年非酒精性脂肪性肝病患者轻度认知功能障碍的相关性[J]. 肝脏, 2024, 29(1): 105-109.
[7]	陈璐, 杨妙芳, 汪芳裕. “口-肠-肝轴”在非酒精性脂肪性肝病中的作用[J]. 肝脏, 2024, 29(1): 110-113.
[8]	刘百怡, 饶慧瑛. 非酒精性脂肪性肝病更名及其影响[J]. 肝脏, 2023, 28(9): 1012-1014.
[9]	孔嘉宁, 施军平. 瘦型非酒精性脂肪性肝病的流行现状与自然转归[J]. 肝脏, 2023, 28(9): 1018-1019.
[10]	张思敏, 袁乙富, 吴小溪, 杜晟楠, 曹勤, 蒋元烨. 不同年龄非酒精性脂肪性肝病合并急性药物性肝损伤患者的临床特点分析[J]. 肝脏, 2023, 28(9): 1088-1092.
[11]	康碧莲, 刘天会. 脂蛋白脂肪酶与非酒精性脂肪性肝病[J]. 肝脏, 2023, 28(9): 1110-1111.
[12]	孙成林, 孙亚朦, 陈姝延, 尤红. 非酒精性脂肪性肝病无创评估的应用与前景[J]. 肝脏, 2023, 28(8): 889-891.
[13]	管炬博, 范建高. 非酒精性脂肪性肝病患者心血管疾病风险的研究进展[J]. 肝脏, 2023, 28(8): 892-893.
[14]	管炬博, 范建高. 非酒精性脂肪性肝病发病的脂肪组织功能障碍学说[J]. 肝脏, 2023, 28(7): 746-748.
[15]	邓朝华, 施军平. 孟德尔随机化分析在非酒精性脂肪性肝病危险因素研究中的应用[J]. 肝脏, 2023, 28(7): 749-750.